IP Library › Granted Patent US 11,801,058
Granted Patent B2
US 11,801,058 · App. 17/192,507 · Granted Oct 31, 2023

Liquid embolic compositions

Inventors: Tai D. Tieu (Fountain Valley, CA); Hideo Morita (Irvine, CA)
Assignee: AccuMedical Beijing Ltd.
A61B17/12113A61B17/12186A61K49/0442A61L24/0015C08L29/04A61L2400/06A61L2430/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,801,058
App. No.
17/192,507
Granted
Oct 31, 2023
Kind
B2
Abstract

The present specification discloses improved liquid embolic compositions, methods of making such liquid embolic compositions, and methods and uses for such liquid embolic compositions.

Claims (39)

1. A liquid embolic composition comprising:

from about 1% to about 20% of a miscible polymer;

from about 5% to about 35% of a radiopaque contrast agent;

from about 5% to about 93% of a biocompatible solvent; and

from about 1% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;

wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.

2. The liquid embolic composition of claim 1 , wherein the composition comprises:

from about 3% to about 10% of a miscible polymer;

from about 20% to about 35% of a radiopaque contrast agent;

from about 15% to about 57% of a biocompatible solvent; and

from about 20% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;

wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.

3. The liquid embolic composition of claim 1 , wherein the miscible polymer is an ethylene vinyl alcohol copolymer.

4. The liquid embolic composition of claim 1 , wherein the contrast agent is at least one of tantalum, tantalum oxide, barium sulfate, gold, platinum, tungsten, palladium, and an iodinated contrast agent.

5. The liquid embolic composition of claim 1 , wherein the biocompatible solvent is dimethyl sulfoxide or a dimethyl sulfoxide homologue.

6. The liquid embolic composition of claim 1 , wherein the mixing agent has a density that is relatively greater than a density of the biocompatible solvent.

7. The liquid embolic composition of claim 6 , wherein the mixing agent is at least one of polypropylene plastic, polyethylene (“PE”), polyethylene terephthalate (“PET”), polytetrafluoroethylene (“PTFE”), polyether ether ketone (“PEEK”), polyaryletherketone (“PAEK,” “PEKK”), and polyetherimide (“PEI”).

8. The liquid embolic composition of claim 7 , wherein the mixing agent has a particle size of about 100 nm to about 1 mm.

9. The liquid embolic composition of claim 8 , wherein the mixing agent has a particle size of about 1,000 nm to about 10,000 nm.

10. The liquid embolic composition of claim 8 , wherein the mixing agent comprises particles having a substantially spherical shape of substantially uniform diameter.

11. The liquid embolic composition of claim 10 , wherein the substantially spherical particles of the mixing agent are multifaceted.

12. The liquid embolic composition of claim 1 , wherein the mixing agent comprises a further material having a density that is relatively less than the density of the contrast agent.

13. The liquid embolic composition of claim 12 , wherein the further material is an at least one gas entrapped within each particle of the contrast agent or mixing agent.

14. The liquid embolic composition of claim 1 , wherein each particle of the contrast agent or mixing agent defines an at least one evacuated void of space therewithin, thereby increasing a buoyancy of the contrast agent or mixing agent.

15. The liquid embolic composition of claim 1 , wherein the contrast agent is integrated in the mixing agent.

16. A method for embolizing a blood vessel using the liquid embolic composition of claim 1 , the method comprising the steps of:

with the liquid embolic composition positioned within a container, shaking the container by hand, thereby causing the mixing agent to agitate the contrast agent in order to create a suspension of the contrast agent within the liquid embolic composition that is fluoroscopically visualizable;

extracting a volume of the liquid embolic composition from the container using a syringe; and

introducing the extracted volume of the liquid embolic composition into the blood vessel via the syringe;

whereby, with the liquid embolic composition positioned within the blood vessel, a precipitate is formed which embolizes the blood vessel.

17. The method of claim 16 , wherein the step of shaking the container by hand further comprises the step of shaking the container by hand for a duration of between 3 and 30 seconds.

18. The method of claim 16 , wherein the step of introducing the extracted volume of the liquid embolic composition into the blood vessel further comprises the step of injecting the extracted volume of embolic composition into the blood vessel at a rate of about 0.05 cc to 0.3 cc per minute.

19. The method of claim 16 , wherein the step of introducing the extracted volume of the liquid embolic composition into the blood vessel further comprises the step of injecting the extracted volume of embolic composition into the blood vessel at a rate of at least 0.6 cc per minute.

20. A liquid embolic composition comprising:

from about 1% to about 20% of a miscible polymer;

from about 5% to about 35% of a radiopaque contrast agent;

from about 5% to about 93% of a biocompatible solvent; and

from about 1% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent and having a density that is relatively greater than a density of the biocompatible solvent, the mixing agent comprising particles having a substantially spherical shape of substantially uniform diameter;

wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.

Assignments (2)
CHANGE OF NAME Recorded Oct 11, 2024
From: ACCUMEDICAL BEIJING LTD.
To: ACCUMEDICAL INC.
Reel/Frame 069166/0876 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: TIEU, TAI D.; MORITA, HIDEO
To: ACCUMEDICAL BEIJING LTD.
Reel/Frame 055569/0874 →
Continuity (1)
Related Publication 20220280163A1 · Sep 8, 2022